Clinical Trial: Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06838910) titled 'Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma' on Feb. 18.

Brief Summary: It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy. The purpose of this study is to evaluate the safety and efficacy of tislelizumab combined with anlotinib as second-line in thymoma and thymic carcinoma.

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Thymic Carcinoma Thymoma

Intervention: DRUG: Experimental: tislelizumab...